Evidence map›Paper›PMID 40663244›Full record

ArticleInvestigational new drugs2025

Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4/6 inhibitor, in Chinese patients with hepatic impairment.

Jia Xu, Jingrui Liu, Yanhua Ding, Xiaoran Yang, Yunjie Fu, Yi Sun

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jia XuPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Jingrui LiuPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China.
Yanhua DingPhase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China. dingyanh@jlu.edu.cn.
Xiaoran YangAVANC PHARMACEUTICAL CO., LTD, Dongzhou Road, Bixi Street, 215513, Changshu City, Jiangsu, China. yangxiaoran@avancpharma.com.
Yunjie FuAVANC PHARMACEUTICAL CO., LTD, Dongzhou Road, Bixi Street, 215513, Changshu City, Jiangsu, China.
Yi SunShanghai Fosun Pharmaceutical Group Co Ltd, Building A, No. 1289 Yishan Road, 200233, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study explored the impact of hepatic impairment on the safety and pharmacokinetics (PK) of FCN-437c, a novel dual CDK4/6 inhibitor for potential breast cancer treatment. In an open-label trial, 25 subjects (8 with mild hepatic impairment, 8 with moderate hepatic impairment, and 8 healthy controls matched for age, sex, and body weight) received a single 200-mg dose of FCN-437c. Results showed that FCN-437c was generally well-tolerated, with no serious adverse events. In mild hepatic impairment group, total FCN-437c C

Indexed as

Antineoplastic AgentsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Liver DiseasesProtein Kinase InhibitorsAdultAgedEast Asian PeopleFemaleHumansMaleMiddle AgedOrganic ChemicalsAntineoplastic AgentsCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FCN-437cOrganic ChemicalsProtein Kinase InhibitorsFCN-437cHepatic impairmentPharmacokineticsSafety

Identifiers

PMID40663244

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.